{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:54:56Z","timestamp":1768348496627,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate whether baseline monosodium urate (MSU) burden estimated by ultrasound (US) predicts the achievement of the 2016 remission criteria for gout after 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this 12-month prospective, observational and single-center study, patients with gout fulfilling all the domains of the 2016 preliminary remission criteria for gout at baseline and on urate-lowering therapy (ULT) for at least the preceding 6 months were consecutively enrolled.<\/jats:p>\n                <jats:p>The US findings indicative of MSU deposits [aggregates, double contour (DC) sign, and\/or tophi] were identified according to the Outcome Measure in Rheumatology US Working Group definitions.<\/jats:p>\n                <jats:p>The US MSU burden was estimated by evaluating elbows, wrists, 2nd metacarpophalangeal joints, knees, ankles, and 1st metatarsophalangeal joints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Remission criteria were fulfilled in 21 (42.0%) out of 50 patients at 12 months. The baseline US MSU burden was significantly lower in patients who achieved remission than in those who did not fulfill the remission criteria at 12 months (1.9\u00b11.8 vs 5.1\u00b13.1, p&lt;0.01).<\/jats:p>\n                <jats:p>US scores and ongoing flare prophylaxis were the only significant predictors of remission with an odds ratio of 10.83 [(95%CI=1.14\u2013102.59), p=0.04] for the absence of MSU deposits, 5.53 [(95%CI=1.34\u201322.76), p&lt;0.01] for the absence of aggregates, 7.33 [(95%CI=1.71\u201331.44), p&lt;0.01] for the absence of DC sign, 3.88 [(95%CI=1.08\u201313.92), p=0.04] for the absence of tophi, and 0.23 [(95%CI=0.07\u20130.75), p=0.02] for ongoing flare prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In gout, baseline US estimation of MSU burden is an independent predictor of the achievement of the remission criteria at 12 months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02568-x","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T05:02:26Z","timestamp":1625806946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: a 12-month study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-8197","authenticated-orcid":false,"given":"Edoardo","family":"Cipolletta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-9377","authenticated-orcid":false,"given":"Jacopo","family":"Di Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-4647","authenticated-orcid":false,"given":"Marco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-7051","authenticated-orcid":false,"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-652X","authenticated-orcid":false,"given":"Fausto","family":"Salaffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-7784","authenticated-orcid":false,"given":"Emilio","family":"Filippucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"10055","key":"2568_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(16)00346-9.","journal-title":"Lancet."},{"issue":"10","key":"2568_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2568_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2568_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879\u201395. https:\/\/doi.org\/10.1002\/art.41247.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2568_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2012.03.010","volume":"42","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155\u201365. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2568_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13075-019-1941-8","volume":"21","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth N, Frampton C, Fung M, Baumgartner S, Nicolaou S, Choi HK. Concurrent validity of provisional remission criteria for gout: A dual-energy CT study. Arthritis Res Ther. 2019;21(1):150. https:\/\/doi.org\/10.1186\/s13075-019-1941-8.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2568_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22741","volume":"68","author":"H de Lautour","year":"2016","unstructured":"de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken). 2016;68(5):667\u201372. https:\/\/doi.org\/10.1002\/acr.22741.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"2568_CR8","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3899\/jrheum.141164","volume":"42","author":"R Grainger","year":"2015","unstructured":"Grainger R, Dalbeth N, Keen H, Durcan L, Edwards NL, Perez-Ruiz F, et al. Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group. J Rheumatol. 2015;42(12):2460\u20134. https:\/\/doi.org\/10.3899\/jrheum.141164.","journal-title":"J Rheumatol"},{"issue":"1","key":"2568_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215315.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2568_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.semarthrit.2017.09.012","volume":"47","author":"YH Lee","year":"2018","unstructured":"Lee YH, Song GG. Diagnostic accuracy of ultrasound in patients with gout: a meta-analysis. Semin Arthritis Rheum. 2018;47(5):703\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.012.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2568_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/art.39959","volume":"69","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Schumacher HR, et al. Performance of ultrasound in the diagnosis of gout in a multicenter study: comparison with monosodium urate monohydrate crystal analysis as the gold standard. Arthritis Rheumatol. 2017;69(2):429\u201338. https:\/\/doi.org\/10.1002\/art.39959.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"2568_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/annrheumdis-2020-217392","volume":"79","author":"HB Hammer","year":"2020","unstructured":"Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Ann Rheum Dis. 2020;79(11):1500\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217392.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2568_CR13","doi-asserted-by":"publisher","first-page":"e001144","DOI":"10.1136\/rmdopen-2019-001144","volume":"6","author":"SN Christiansen","year":"2020","unstructured":"Christiansen SN, \u00d8stergaard M, Slot O, Keen H, Bruyn GAW, D'Agostino MA, et al. Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy. RMD Open. 2020;6(1):e001144. https:\/\/doi.org\/10.1136\/rmdopen-2019-001144.","journal-title":"RMD Open"},{"issue":"6","key":"2568_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jbspin.2020.09.014","volume":"87","author":"E Ebstein","year":"2020","unstructured":"Ebstein E, Forien M, Norkuviene E, Richette P, Mouterde G, Daien C, et al. Ultrasound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): duration of flare prophylaxis. Joint Bone Spine. 2020;87(6):647\u201351. https:\/\/doi.org\/10.1016\/j.jbspin.2020.09.014.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"2568_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/rheumatology\/key303","volume":"58","author":"E Ebstein","year":"2019","unstructured":"Ebstein E, Forien M, Norkuviene E, Richette P, Mouterde G, Daien C, et al. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. Rheumatology (Oxford). 2019;58(3):410\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/key303.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2568_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3899\/jrheum.090370","volume":"36","author":"HR Schumacher","year":"2009","unstructured":"Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36(10):2342\u20135. https:\/\/doi.org\/10.3899\/jrheum.090370.","journal-title":"J Rheumatol"},{"issue":"7","key":"2568_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3899\/jrheum.110271","volume":"38","author":"JA Singh","year":"2011","unstructured":"Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38(7):1452\u20137. https:\/\/doi.org\/10.3899\/jrheum.110271.","journal-title":"J Rheumatol"},{"issue":"3","key":"2568_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Sing JA, Rahn EJ, Mudano AS, et al. Brief Report: Validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70(3):462\u20137. https:\/\/doi.org\/10.1002\/art.40381.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2568_CR19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","volume":"78","author":"D Bursill","year":"2019","unstructured":"Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592\u2013600. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215933.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2568_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/acr.22009","volume":"65","author":"M Guti\u00e9rrez","year":"2013","unstructured":"Guti\u00e9rrez M, Di Geso L, Rovisco J, Di Carlo M, Ariani A, Filippucci E, et al. Ultrasound learning curve in gout: a disease-oriented training program. Arthritis Care Res (Hoboken). 2013;65(8):1265\u201374. https:\/\/doi.org\/10.1002\/acr.22009.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"2568_CR21","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2013-203487","volume":"73","author":"E Naredo","year":"2014","unstructured":"Naredo E, Uson J, Jim\u00e9nez-Palop M, Martinez A, Vicente E, Brito E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2014;73(8):1522\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203487.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2568_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jbspin.2018.06.008","volume":"86","author":"A Di Matteo","year":"2019","unstructured":"Di Matteo A, Filippucci E, Cipolletta E, Ausili M, Martire V, Di Carlo M, et al. The popliteal groove region: a new target for the detection of monosodium urate crystal deposits in patients with gout. An ultrasound study. Joint Bone Spine. 2019;86(1):89\u201394. https:\/\/doi.org\/10.1016\/j.jbspin.2018.06.008.","journal-title":"Joint Bone Spine"},{"issue":"12","key":"2568_CR23","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1136\/annrheumdis-2017-211585","volume":"76","author":"I M\u00f6ller","year":"2017","unstructured":"M\u00f6ller I, Janta I, Backhaus M, Ohrndorf S, Bong DA, Martinoli C, et al. The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. Ann Rheum Dis. 2017;76(12):1974\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211585.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2568_CR24","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.3899\/jrheum.150366","volume":"42","author":"L Terslev","year":"2015","unstructured":"Terslev L, Gutierrez M, Christensen R, Balint PV, Bruyn GA, Delle Sedie A, et al. Assessing elementary lesions in gout by ultrasound: results of an OMERACT patient-based agreement and reliability exercise. J Rheumatol. 2015;42(11):2149\u201354. https:\/\/doi.org\/10.3899\/jrheum.150366.","journal-title":"J Rheumatol"},{"issue":"1 Suppl 80","key":"2568_CR25","first-page":"S42","volume":"32","author":"E Filippucci","year":"2014","unstructured":"Filippucci E, Di Geso L, Girolimetti R, Grassi W. Ultrasound in crystal-related arthritis. Clin Exp Rheumatol. 2014;32(1 Suppl 80):S42\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"2568_CR26","doi-asserted-by":"publisher","first-page":"vii18","DOI":"10.1093\/rheumatology\/kes332","volume":"51","author":"E Filippucci","year":"2012","unstructured":"Filippucci E, Di Geso L, Grassi W. Tips and tricks to recognize microcrystalline arthritis. Rheumatology (Oxford). 2012;51:vii18\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/kes332.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2568_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41584-019-0280-0","volume":"15","author":"T Bardin","year":"2019","unstructured":"Bardin T, Richette P. Defining remission in patients with gout. Nat Rev Rheumatol. 2019;15(9):516\u20137. https:\/\/doi.org\/10.1038\/s41584-019-0280-0.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2568_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3899\/jrheum.190386","volume":"47","author":"E Pascual","year":"2020","unstructured":"Pascual E, Andr\u00e9s M, Sivera F. Is remission a valid target for gout? J Rheumatol. 2020;47(1):4\u20135. https:\/\/doi.org\/10.3899\/jrheum.190386.","journal-title":"J Rheumatol"},{"issue":"1","key":"2568_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","volume":"82","author":"S Ottaviani","year":"2015","unstructured":"Ottaviani S, Gill G, Aubrun A, Palazzo E, Meyer O, Dieud\u00e9 P. Ultrasound in gout: a useful tool for following urate-lowering therapy. Joint Bone Spine. 2015;82(1):42\u20134. https:\/\/doi.org\/10.1016\/j.jbspin.2014.03.011.","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2568_CR30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/art.40929","volume":"71","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth N, Billington K, Doyle A, Framptom C, Tan P, Aati O, et al. Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol. 2019;71(10):1739\u201346. https:\/\/doi.org\/10.1002\/art.40929.","journal-title":"Arthritis Rheumatol"},{"key":"2568_CR31","doi-asserted-by":"publisher","unstructured":"Dalbeth N, Stamp LK, Taylor WJ. What is remission in gout and how should we measure it? published online first: 15 December 2020. Rheumatology (Oxford). 2021. https:\/\/doi.org\/10.1093\/rheumatology\/keaa853.","DOI":"10.1093\/rheumatology\/keaa853"},{"issue":"10","key":"2568_CR32","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1136\/annrheumdis-2014-205431","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015;74(10):1868\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205431.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2568_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semarthrit.2019.01.004","volume":"49","author":"S Stewart","year":"2019","unstructured":"Stewart S, Maxwell H, Dalbeth N. Prevalence and discrimination of OMERACT-defined elementary ultrasound lesions of gout in people with asymptomatic hyperuricaemia: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;49(1):62\u201373. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.004.","journal-title":"Semin Arthritis Rheum."},{"issue":"5","key":"2568_CR34","first-page":"746","volume":"35","author":"D Peiteado","year":"2017","unstructured":"Peiteado D, Villalba A, Mart\u00edn-Mola E, Balsa A, De Miguel E. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment. Clin Exp Rheumatol. 2017;35(5):746\u201351.","journal-title":"Clin Exp Rheumatol"},{"key":"2568_CR35","doi-asserted-by":"publisher","unstructured":"Christiansen SN, \u00d8stergaard M, Slot O, Fana V, Terslev L. Ultrasound for the diagnosis of gout\u2014the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group. Rheumatology (Oxford) Published Online First: 22 July 2020. doi:https:\/\/doi.org\/10.1093\/rheumatology\/keaa36627","DOI":"10.1093\/rheumatology\/keaa36627"},{"issue":"1","key":"2568_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1381-2","volume":"19","author":"T Pascart","year":"2017","unstructured":"Pascart T, Grandjean A, Norberciak L, Ducoulombier V, Motte M, Luraschi H, et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. Arthritis Res Ther. 2017;19(1):1\u20138. https:\/\/doi.org\/10.1186\/s13075-017-1381-2.","journal-title":"Arthritis Res Ther"},{"key":"2568_CR37","doi-asserted-by":"publisher","unstructured":"Ea H, Gauffenic A, Nguyen QD, Pham NG, Olivier O, Frochot V, et al. Calcium pyrophosphate crystal deposition in gouty tophi. Arthritis Rheumatol Published Online First: 10 September 2020. https:\/\/doi.org\/10.1002\/art.41515.","DOI":"10.1002\/art.41515"},{"issue":"5","key":"2568_CR38","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4281","volume":"15","author":"C Scir\u00e8","year":"2013","unstructured":"Scir\u00e8 C, Manara M, Cimmino M, Govoni M, Salaffi F, Punzi L, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013;15(5):R101. https:\/\/doi.org\/10.1186\/ar4281.","journal-title":"Arthritis Res Ther"},{"key":"2568_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13047-016-0183-0","volume":"10","author":"S Stewart","year":"2017","unstructured":"Stewart S, Dalbeth N, Vandal AC, Allen B, Miranda R, Rome K. Are ultrasound features at the first metatarsophalangeal joint associated with clinically-assessed pain and function? A study of people with gout, asymptomatic hyperuricaemia and normouricaemia. J Foot Ankle Res. 2017;10:1\u20138.","journal-title":"J Foot Ankle Res"},{"issue":"11","key":"2568_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654\u201361. https:\/\/doi.org\/10.1038\/nrrheum.2014.124.","journal-title":"Nat Rev Rheumatol"},{"key":"2568_CR41","doi-asserted-by":"publisher","unstructured":"P\u00e9rez Ruiz F, Richette P, Stack AG, Gurunath RK, Jesus Garc\u00eda de Y\u00e9benes M, Carmona L. Failure to reach uric acid target of <0.36 mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open 2019;5:1015. doi:https:\/\/doi.org\/10.1136\/rmdopen-2019-001015, 2","DOI":"10.1136\/rmdopen-2019-001015"},{"issue":"10","key":"2568_CR42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","volume":"4","author":"AS Klauser","year":"2019","unstructured":"Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 2019;4(10):1019\u201328. https:\/\/doi.org\/10.1001\/jamacardio.2019.3201.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2568_CR43","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert. Arthritis Rheumatol. 2018;70(11):1702\u20139. https:\/\/doi.org\/10.1002\/art.40583.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"2568_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/acr2.1025","volume":"1","author":"N Schlesinger","year":"2019","unstructured":"Schlesinger N, Edwards NL, Khanna PP, Yeo AE, Lipsky PE. Evaluation of proposed criteria for remission and evidence-based development of criteria for complete response in patients with chronic refractory gout. ACR Open Rheumatol. 2019;1(4):236\u201343. https:\/\/doi.org\/10.1002\/acr2.1025.","journal-title":"ACR Open Rheumatol."},{"key":"2568_CR45","doi-asserted-by":"crossref","unstructured":"Alvarado-de la Barrera C, L\u00f3pez-L\u00f3pez CO, \u00c1lvarez-Hern\u00e1ndez E, Pel\u00e1ez-Ballestas I, G\u00f3mez-Ruiz C, Burgos-Vargas R, et al. Are target urate and remission possible in severe gout? A five-year cohort study. J Rheumatol. 2020;47:132-9. doi:10.3899\/jrheum.181214","DOI":"10.3899\/jrheum.181214"},{"issue":"1","key":"2568_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1714-9","volume":"20","author":"T Pascart","year":"2018","unstructured":"Pascart T, Grandjean A, Capon B, Legrand J, Namane N, Ducoulombier V, et al. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study: MSU burden and risk of gout flare. Arthritis Res Ther. 2018;20(1):1\u20139. https:\/\/doi.org\/10.1186\/s13075-018-1714-9.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2568_CR47","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/acr.22844","volume":"68","author":"CA Scir\u00e8","year":"2016","unstructured":"Scir\u00e8 CA, Carrara G, Viroli C, Cimmino MA, Taylor WJ, Manara M, et al. Development and first validation of a disease activity score for gout. Arthritis Care Res (Hoboken). 2016;68(10):1530\u20137. https:\/\/doi.org\/10.1002\/acr.22844.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"2568_CR48","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/acr.22855","volume":"68","author":"A Abhishek","year":"2016","unstructured":"Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: a case-control study. Arthritis Care Res (Hoboken). 2016;68(10):1573\u20137. https:\/\/doi.org\/10.1002\/acr.22855.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"2568_CR49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3899\/jrheum.150345","volume":"43","author":"N Schlesinger","year":"2016","unstructured":"Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR. Gout prophylaxis evaluated according to the 2012 American College of Rheumatology guidelines: analysis from the CORRONA Gout Registry. J Rheumatol. 2016;43(5):924\u201330. https:\/\/doi.org\/10.3899\/jrheum.150345.","journal-title":"J Rheumatol"},{"issue":"11","key":"2568_CR50","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","volume":"53","author":"A Latourte","year":"2014","unstructured":"Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53(11):1920\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/keu157.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2568_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semarthrit.2019.11.009","volume":"50","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Brunetti L. Beyond urate lowering: analgesic and anti-inflammatory properties of allopurinol. Semin Arthritis Rheum. 2020;50(3):444\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2568_CR52","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.berh.2020.101595","volume":"34","author":"E Filippucci","year":"2020","unstructured":"Filippucci E, Reginato AM, Thiele RG. Imaging of crystalline arthropathy in 2020. Best Pract Res Clin Rheumatol. 2020;34(6):101595. https:\/\/doi.org\/10.1016\/j.berh.2020.101595.","journal-title":"Best Pract Res Clin Rheumatol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02568-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T05:04:16Z","timestamp":1625807056000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2568"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02568-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethics Committee (<i>Comitato Etico Regione Marche -<\/i> id CERM: 168\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MDC has received speaking fees from AbbVie, Novartis, Pfizer, and Sanofi Aventis. FS has received speaking fees from AbbVie, AlfaWassermann, Biogen, Bristol-Myers Squibb, Novartis, and Pfizer. WG has received speaking fees from AbbVie, Celgene, Gr\u00fcnenthal, Pfizer, and Union Chimique Belge Pharma. EF has received speaking fees from AbbVie, Bristol-Myers Squibb, Janssen-Cilag, Novartis, Pfizer, Roche, and Union Chimique Belge Pharma. All other authors have declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}